 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...5253545556575859606162...132133» |
- |||| everolimus / Generic mfg.
Clinical: Very nice paper from @adib_elio #DJK @DanaFarber @BrighamWomens and colleagues @sloan_kettering about how complex the TOR pathway can be and with a prospective study here with everolimus in a genomically- selected population, ORR still <10%. (Twitter) - Mar 22, 2021
- | Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Combination therapy: A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection (clinicaltrials.gov) - Mar 21, 2021
P1, N=24, Recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Jun 2021
- |||| Inlyta (axitinib) / Pfizer, Torisel (temsirolimus) / Pfizer
Clinical: That is great. We did clinical trials @VUMChealth between ‘09-‘14. When he first started there were only 2 approved RCC drugs available! I like to think Don’s trials of Avaston, Inlyta, Afinitor & Torisel made a difference in somone’s else’s survival. #hope (Twitter) - Mar 20, 2021
- || sirolimus / Generic mfg.
Biomarker, Clinical, Journal: Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. (Pubmed Central) - Mar 20, 2021
Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Jun 2021 Sirolimus is a potentially effective treatment option for patients with HR-positive advanced breast cancer.
- || everolimus / Generic mfg.
Clinical, Journal: Time to Conversion to an Everolimus-Based Regimen: Renal Outcomes in Liver Transplant Recipients From the EVEROLIVER Registry. (Pubmed Central) - Mar 20, 2021
Data from this real-life use of everolimus indicate that renal function was maintained from pre-conversion until Month 36 even in patients with advanced CKD. However, early rather than late conversion appears to be a safe approach to preserve long-term renal function in LTR.
- everolimus / Generic mfg.
[VIRTUAL] INCIDENTAL SKIN CANCER AFTER KIDNEY TRANSPLANTATION: A REGIONAL POPULATION BASEDCOHORT STUDY (2015-2020) (Mini-Orals Hall) - Mar 19, 2021 - Abstract #ERAEDTA2021ERA_EDTA_697;
A significant percentage (45%) was during the first year, earlier in aged patients. • The use of MMF þ Tac was associated with a higher prevalence of skin cancer malignancies and an increased risk of multiple and mixed lesions.
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] ATYPICAL HEMOLYTIC UREMIC SYNDROME IN LUNG TRANSPLANTATION: TREATMENT WITH ECULIZUMAB, OUR EXPERIENCE. (Mini-Orals Hall) - Mar 19, 2021 - Abstract #ERAEDTA2021ERA_EDTA_637;
Patients are at risk of end stage renal disease. Eculizumab treatment appears promising.
- | Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. (Pubmed Central) - Mar 19, 2021
Post IO-VEGF, most patients received VEGFR-TKIs. In this setting, VEGFR-TKIs demonstrated clinical activity and remain a viable option for salvage therapy after progression on IO-VEGF.
- | everolimus / Generic mfg.
Preclinical, Journal: Everolimus reduces postoperative arthrofibrosis in rabbits by inducing autophagy-mediated fibroblast apoptosis by PI3K/Akt/mTOR signaling pathway. (Pubmed Central) - Mar 19, 2021
In this setting, VEGFR-TKIs demonstrated clinical activity and remain a viable option for salvage therapy after progression on IO-VEGF. Everolimus can reduce surgery-induced knee fibrosis by inducing autophagy-mediated fibroblast apoptosis, which may be involved with the regulation of the PI3K/Akt/mTOR signaling pathway.
- || everolimus / Generic mfg.
Clinical, Journal: Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus. (Pubmed Central) - Mar 19, 2021
CDK 4/6 inhibitors and hormonal treatment can lead to increased vascular inflammation, and higher blood pressure compared to the combination of everolimus and hormonal treatment. Moreover, both treatment strategies promoted left ventricle remodeling.
- everolimus / Generic mfg.
[VIRTUAL] Meningioma with leptomeningeal dissemination () - Mar 18, 2021 - Abstract #AAN2021AAN_1987;
Although multiple meningiomas can occur after radiation, a short latency could suggest leptomeningeal dissemination as an etiology for such presentation. The behavior and response to treatment of such tumors are difficult to predict.
- || everolimus / Generic mfg.
Clinical, Journal: Developmental outcomes in children/adolescents and one adult with tuberous sclerosis complex (TSC) and refractory epilepsy treated with everolimus. (Pubmed Central) - Mar 17, 2021
While developmental disorders were prominent, we observed an overall progression at a slower pace. Despite a positive effect on seizure occurrence, treatment with EVO did not reverse developmental problems in the observation period of this study.
- | everolimus / Generic mfg., sirolimus / Generic mfg.
Journal: The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis. (Pubmed Central) - Mar 17, 2021
EVE is an effective treatment option for the management of several malignancies and is often combined with other therapies, such as radiation, for a more efficient response. However, an increased risk of pulmonary fibrosis should also be anticipated when these two modalities are combined, as they both can cause pulmonary damage, especially when administered concurrently.
- | cyclophosphamide / Generic mfg., everolimus / Generic mfg.
Trial completion, Post-transplantation: OCTET-Ever: Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT (clinicaltrials.gov) - Mar 17, 2021
P2, N=19, Completed, Sponsor: University of Cologne
However, an increased risk of pulmonary fibrosis should also be anticipated when these two modalities are combined, as they both can cause pulmonary damage, especially when administered concurrently. Active, not recruiting --> Completed
- ||||| New P1/2 trial: MORPHEUS BC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (clinicaltrials.gov) - Mar 17, 2021
P1/2, N=255, Recruiting, Sponsor: Hoffmann-La Roche
- | Mekinist (trametinib) / Novartis, BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, New trial, Metastases: Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors (clinicaltrials.gov) - Mar 16, 2021
P=N/A, N=1, Recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
- || everolimus / Generic mfg.
Clinical, Journal: An open-label randomized clinical trial to evaluate the efficacy of everolimus versus tacrolimus in triple maintenance immunosuppressive therapy for kidney transplant patients. (Pubmed Central) - Mar 16, 2021
This clinical trial showed that the EVL+MMF+PRED triple maintenance therapy was efficacious compared with TAC during 32 months of follow-up. However, further studies are needed to confirm the efficacy of this regimen for long-term graft survival.
- | everolimus / Generic mfg.
Journal: Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes. (Pubmed Central) - Mar 16, 2021
We observed sustained improvements in lung function for CLAD related to BOS subgroup results, whereas RAS confirmed the 1-year worsening functional trend. Data seem to suggest one more piece of the puzzle in CLAD phenotyping.
- ||| everolimus / Generic mfg.
Clinical: So excited to join @CharisEngMDPhD to give update about phase #2 clinical trial , double blinded randomized study to examine the safety and efficacy of Everolimus in #PTEN patients. (Twitter) - Mar 15, 2021
- ||| everolimus / Generic mfg.
Clinical: A randomized double-blind controlled trial of everolimus in individuals with #PTEN mutations Study design and statistical considerations https://t.co/3mxBqQGCji (Twitter) - Mar 15, 2021
- ||||| Obnitix (MSC-FFM) / Medac
Trial completion date, Trial initiation date, Trial primary completion date, Stroma: IDUNN: Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (clinicaltrials.gov) - Mar 15, 2021
P3, N=210, Not yet recruiting, Sponsor: medac GmbH
Data seem to suggest one more piece of the puzzle in CLAD phenotyping. Trial completion date: Sep 2025 --> Dec 2025 | Initiation date: Mar 2021 --> Jun 2021 | Trial primary completion date: Sep 2023 --> Jan 2024
- |||| everolimus / Generic mfg.
mTOR is fascinating and still not optimized therapeutic option in #cancer #treatment. In my view, Everolimus, as mTOR of choice in studies is a mTOR plateau that seeks a step up to plan, design and improve mTOR potential. Challenging, but achievable! #oncology (Twitter) - Mar 13, 2021
- ||||| Zelboraf (vemurafenib) / Roche
Clinical, Combination therapy: Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF Mutated Malignancies https://t.co/hPVsNxrv0a (Twitter) - Mar 13, 2021
- ||| Caprelsa (vandetanib) / Sanofi
👉Preclinical studies suggest that combining vandetanib with everolimus (EV), may improve antitumor activity. We determined the safety, MTD,DLT & PR2D of VAN + EV in patients with advanced cancer https://t.co/t4ncBaG6Ne (Twitter) - Mar 13, 2021
- ||||| Caprelsa (vandetanib) / Sanofi
Clinical: 🚨⭐️ Hot off the press 👉Safety and activity of vandetanib + everolimus in patients with advanced solid tumors @myESMO @ESMO_Open @OncoAlert @IshwariaMD https://t.co/t4ncBaG6Ne (Twitter) - Mar 13, 2021
- cisplatin / Generic mfg.
[VIRTUAL] Preclinical efficacy of platinum based chemotherapy regimens and targeted therapeutics in the first successful described patient derived xenograft model of mixed acinar neuroendocrine carcinoma of the pancreas () - Mar 13, 2021 - Abstract #AACR2021AACR_4587;
No synergistic effect observed in sunitinib/everolimus. Preclinical studies are undergoing to investigate other effective and less toxic therapeutics for MANEC.
- everolimus / Generic mfg.
[VIRTUAL] Everolimus mediated Radioprotection on surrounding healthy tissue in glioblastoma microbrain models () - Mar 13, 2021 - Abstract #AACR2021AACR_4407;
Our findings suggest that pretreatment with low-dose Everolimus may protect NSPCs from radiation induced injuries after radiation therapy, while maintaining radiation sensitivity to GBM cells. This study suggests low-dose Everolimus as a potential radio-protector for clinical treatment of glioblastoma and other brain malignancies.
- palcitoclax (APG-1252) / Ascentage Pharma
[VIRTUAL] Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN) () - Mar 13, 2021 - Abstract #AACR2021AACR_4354;
Concurrent expression of BCL-xL and MCL-1 proteins suggests that a combination treatment targeting both proteins might be more effective in NEN. Our findings inform development of a BCL-2/BCL-xL inhibitor for NEN therapy.
- RMC-5552 / Revolution Medicines
[VIRTUAL] Discovery of RMC-5552: A selective bi-steric inhibitor of mTORC1 that suppresses 4EBP1 phosphorylation, for the treatment of mTORC1-activated tumors including RAS pathway escape (Channel 02) - Mar 13, 2021 - Abstract #AACR2021AACR_4140;
In addition, we will show single agent activity of bi-steric mTORC1 inhibitors in preclinical models of tumors bearing PI3K/mTOR pathway alterations as primary drivers, including PTEN-deficient glioblastoma multiforme, TSC1/2-deficient renal cystadenoma cancer, and hepatocellular cancers harboring mTOR-activating β-catenin mutations. RMC-5552, through reactivation of 4EBP1 and inhibition of cap-dependent translation, has the potential to benefit cancer patients with genetically-defined tumors with activating mutations in the RAS and PI3K/mTOR pathways both as a single agent or in combination with RAS inhibitors.
- | everolimus / Generic mfg.
Journal: Resumé of the challenges and burden of living with transplanted hearts for >31 years. (Pubmed Central) - Mar 13, 2021
Hyperlipidemia, mostly hypercholesterolemia occurs especially in patients on tacrolimus or everolimus...Nonetheless, it is burdened by chronic allograft vasculopathy and immunosuppression sequelae, the main limiting factors for survival, which needed to be constantly addressed throughout their lifetime. This brief report provides an insight into the challenges and burden patients living >31 years with transplanted hearts are confronted with.
- everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Monotherapy: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma (clinicaltrials.gov) - Mar 12, 2021
P2, N=4, Active, not recruiting, Sponsor: Jonsson Comprehensive Cancer Center
This brief report provides an insight into the challenges and burden patients living >31 years with transplanted hearts are confronted with. Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Feb 2021 --> Feb 2022
- || everolimus / Generic mfg.
Trial completion date, Trial primary completion date: A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients (clinicaltrials.gov) - Mar 12, 2021
P=N/A, N=12, Recruiting, Sponsor: Roberto Gedaly
Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Feb 2021 --> Feb 2022 Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
- |||| Solucin (177Lu-edotreotide) / ITM Isotopen Technologien Munchen
Trial completion date, Trial primary completion date: COMPETE: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (clinicaltrials.gov) - Mar 12, 2021
P3, N=300, Recruiting, Sponsor: ITM Solucin GmbH
Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022 Trial completion date: May 2024 --> Jun 2029 | Trial primary completion date: Dec 2023 --> Jun 2024
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: New Treatments Emerge for RCC. (Pubmed Central) - Mar 12, 2021
In one, the combination of lenvatinib and pembrolizumab was superior to sunitinib and to lenvatinib plus everolimus in clear-cell RCC. In the other, cabozantinib was more effective than sunitinib in papillary RCC.
- || everolimus / Generic mfg.
I will at least give them credit for not using everolimus as the control! (Twitter) - Mar 11, 2021
- |||| belzutifan (MK-6482) / Merck (MSD)
Clinical, FDA event: Question: Given this data and FDA approval as SOC in 3rd line #mrcc, does this change thinking about use of everolimus as comparator in Ph3 trial vs belzutifan? Thoughts? #clinicaltrials #kidneycancer (Twitter) - Mar 11, 2021
- KPT-9274 / Karyopharm, Sutent (sunitinib) / Pfizer
[VIRTUAL] Novel targets for therapy resistant pancreatic neuroendocrine tumors () - Mar 11, 2021 - Abstract #AACR2021AACR_3725;
Current therapeutic approaches for advanced PNET patients include chemotherapy (Capecitabine, Temolozomide, 5FU etc), targeted therapies (everolimus, and sunitinib), hormonal therapies [somatostatin analogs (octreotide or lanreotide)] and the novel peptide receptor radionuclide therapy...Importantly, combination treatment of KPT-9274 (150mg/kg) and everolimus (2.5 mg/kg used at sub-optimal dose) caused reduction of PNET xenografts. Our investigations demonstrate that PAK4 and NAMPT are two viable therapeutic targets in the difficult to treat PNETs that warrant further clinical investigations.
- everolimus / Generic mfg.
[VIRTUAL] COMPETE Phase III Trial - Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide vs. Everolimus in Progressive GEP-NET () - Mar 11, 2021 - Abstract #AACR2021AACR_3265;
P3
It is expected that COMPETE will increase their treatment options, including 1st-line therapy. Further studies with 177Lu-Edotreotide in NET patients with high unmet medical need are under review.
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
[VIRTUAL] Next-generation sequencing of the primary and recurrent tumors from patients with extranodal natural killer/T cell lymphoma () - Mar 11, 2021 - Abstract #AACR2021AACR_3053;
Additional mutations can be found in recurrent tumors but the relationship between the acquisition of new mutations and the treatment received was still poorly understood. TSC2 and RAD54L mutations were identified in some recurrent tumors which may serve as potential therapeutic targets for ENKTL.
- [VIRTUAL] Combination screening of KRASG12C specific inhibitors with other targeted therapies in patient-derived multicellular tumor spheroids () - Mar 11, 2021 - Abstract #AACR2021AACR_2891;
Lastly, both KRASG12C inhibitors and abemaciclib, demonstrated additive to greater than additive cytotoxicity in the pancreatic cancer cell line 323965-272-R-J2, but this outcome was not observed with the CDK4/6 inhibitor, palbociclib, or in the other KRASG12C variant cell lines. These preclinical findings provide guidance regarding selection of combination regimens with KRASG12C inhibitors that may result in increased clinical efficacy.
- [VIRTUAL] Impact of baseline culture condition on the growth and treatment response of mouse derived cancer organoids () - Mar 11, 2021 - Abstract #AACR2021AACR_2221;
Mouse derived cancer organoids are a useful tool in modeling drug response of cancers with specific mutational profiles. While the baseline size of MDCOs can change the growth rate, the growth rate and treatment response of MDCOs is not impacted by the passage number, plating density, location within the Matrigel, and from which mouse the MDCOs were derived.
- Vanflyta (quizartinib) / Daiichi Sankyo
[VIRTUAL] Targeting ATM kinase and mTOR signaling reverses bone marrow stromal cell-mediated protection of FLT3-ITD AML from FLT3-targeted therapy () - Mar 11, 2021 - Abstract #AACR2021AACR_1040;
These data suggest that ATM kinase and mTOR signaling play a key role in bone marrow stoma-mediated protection against FLT3 targeted therapy. Findings from this research provide new insights into the mechanism of bone marrow stroma-mediated protection of FLT3-ITD AML from FLT3-targeted therapy, identifying additional candidates for combinatorial therapies designed to overcome the protective effects of bone marrow stromal cells and improve patient outcomes.
- LY3484356 / Eli Lilly
[VIRTUAL] Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD) () - Mar 11, 2021 - Abstract #AACR2021AACR_443;
P1a/1b
LY3484356 has shown synergy or additivity in combination with CDK4/6 inhibitor abemaciclib, mTOR inhibitor everolimus and PIK3CA inhibitor alpelisib in inhibiting cell proliferation in ER+ breast cancer cell lines in vitro and tumor growth inhibition in relevant xenograft or PDX models in vivo. The first-in-human Phase 1/2 clinical trial of LY3484356 (EMBER, ClinicalTrials.gov NCT04188548) is currently ongoing and a window-of-opportunity study evaluating the pharmacodynamic effects of LY3484356 in early stage breast cancer is expected to begin early 2021.
- | sirolimus / Generic mfg.
Preclinical, Journal: Evaluation of a coated blade spray-tandem mass spectrometry assay as a new tool for the determination of immunosuppressive drugs in whole blood. (Pubmed Central) - Mar 11, 2021
The results demonstrate that CBS-MS/MS is a suitable alternative to conventional methodologies for monitoring of ISDs from whole blood in a clinical setting. Graphical abstract.
- || Sutent (sunitinib) / Pfizer
Biomarker, Review, Journal: Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. (Pubmed Central) - Mar 11, 2021
Great progress has been achieved in the combination of systematic therapy with local control treatments. The optimal timing of local control intervention, planning of sequential therapies, and implementation of multidisciplinary care remain pending.
- | everolimus / Generic mfg.
Journal: In Silico Analyses and Cytotoxicity Study of Asiaticoside and Asiatic Acid from Malaysian Plant as Potential mTOR Inhibitors. (Pubmed Central) - Mar 11, 2021
Everolimus, an mTOR inhibitor, was used as a standard compound for the comparative analysis...Interestingly, this is the first study of asiaticoside and asiatic acid against tuberous sclerosis complex (TSC) disease model by targeting mTOR. These results, coupled with our in silico findings, should prompt further studies, to clarify the mode of action, safety, and efficacy of these compounds as mTOR inhibitors.
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change, Metastases: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Mar 10, 2021
P1, N=27, Completed, Sponsor: City of Hope Medical Center
These results, coupled with our in silico findings, should prompt further studies, to clarify the mode of action, safety, and efficacy of these compounds as mTOR inhibitors. Active, not recruiting --> Completed | N=45 --> 27
- |||| letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 10, 2021
P2, N=203, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=45 --> 27 Active, not recruiting --> Completed
- everolimus / Generic mfg.
[VIRTUAL] Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence () - Mar 9, 2021 - Abstract #ESMOBC2021ESMO_BC_274;
Active, not recruiting --> Completed Given that prior CDK4/6i was not associated with worse treatment outcomes to EVE, EVE-based regimen could be considered one of the reasonable treatment options after CDK4/6i.
- everolimus / Generic mfg.
[VIRTUAL] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC) () - Mar 9, 2021 - Abstract #ESMOBC2021ESMO_BC_264;
PAM50 subtype remains prognostic in this context. Primary CDK4/6i refractory tumors might benefit more from CT than ET.